Andrés Planells‐Cárcel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Andrés Planells‐Cárcel has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Elena Valera-García
Departmento de Biotecnología de Alimentos Instituto de Agroquímica y Tecnología de Alimentos (IATA)—Consejo Superior de Investigaciones Científicas (CSIC) Valencia Spain
1 shared publication - Guillermo Quintás
Health and Biomedicine, Leitat Technological Center, Barcelona, Spain
1 shared publication - Jose Luis Martinez
Section of Synthetic Biology (DTU Bioengineering), Department of Biotechnology and Biomedicine, Technical University of Denmark, Lyngby, Denmark
1 shared publication - José Manuel Guillamón
Institute of Agrochemistry and Food Technology (IATA-CSIC)
1 shared publication - Sara Muñiz‐Calvo
Departmento de Biotecnología de Alimentos Instituto de Agroquímica y Tecnología de Alimentos (IATA)—Consejo Superior de Investigaciones Científicas (CSIC) Valencia Spain
1 shared publication
Latest Publications
- Open Access
- 5 April 2025
- Published by Wiley in Microbial Biotechnology
- Vol. 18 (4) , e70140
Metabolic Engineering of a Serotonin Overproducing Saccharomyces cerevisiae Strain
The EU Green Deal prioritises the transformation of the chemical industry to a more environmentally sustainable model. This involves using microorganisms, such as Saccharomyces cerevisiae , to produce molecules more sustainably through biotechnological approaches. In this study, we demonstrate an example of serotonin production using S. cerevisiae as a cell factory, along with its optimisation and upscaling. To achieve this, we introduced two heterologous genes, the combination of tryptophan decarboxylase from Clostridium sporogenes ( Cs TDC) and tryptamine 5‐hydroxylase from Oryza sativa ( Os T5H), to complete the serotonin biosynthetic pathway using L‐tryptophan (L‐TRP) as a precursor. By modifying ARO4 to a feedback‐resistant version ( ARO4 *), the flux of the shikimate pathway was significantly increased and serotonin production was achieved at levels up to 120 mg/L directly from the glucose source. After a medium optimisation, a final concentration of 80 g/L glucose and 300 mg/L of nitrogen resulted in better conditions for increasing serotonin titres. Using this medium in a 1 L bioreactor fermentation resulted in approximately 250 mg/L of serotonin. A targeted metabolomic study of the bioreactor growth medium identified potential bottlenecks in the serotonin‐overproducing strain and future targets for increasing its titre. We have constructed a strain of S. cerevisiae that represents the first steps towards feasible industrial production of serotonin using a sustainable and environmentally friendly approach, paving the way for the development of similar biotechnological strategies in the future.
- 5 April 2025
- Published by Wiley in Microbial Biotechnology
- Vol. 18 (4) , e70140
Open AccessMetabolic Engineering of a Serotonin Overproducing Saccharomyces cerevisiae Strain
The EU Green Deal prioritises the transformation of the chemical industry to a more environmentally sustainable model. This involves using microorganisms, such as Saccharomyces cerevisiae , to produce molecules more sustainably through biotechnological approaches. In this study, we demonstrate an example of serotonin production using S. cerevisiae as a cell factory, along with its optimisation and upscaling. To achieve this, we introduced two heterologous genes, the combination of tryptophan decarboxylase from Clostridium sporogenes ( Cs TDC) and tryptamine 5‐hydroxylase from Oryza sativa ( Os T5H), to complete the serotonin biosynthetic pathway using L‐tryptophan (L‐TRP) as a precursor. By modifying ARO4 to a feedback‐resistant version ( ARO4 *), the flux of the shikimate pathway was significantly increased and serotonin production was achieved at levels up to 120 mg/L directly from the glucose source. After a medium optimisation, a final concentration of 80 g/L glucose and 300 mg/L of nitrogen resulted in better conditions for increasing serotonin titres. Using this medium in a 1 L bioreactor fermentation resulted in approximately 250 mg/L of serotonin. A targeted metabolomic study of the bioreactor growth medium identified potential bottlenecks in the serotonin‐overproducing strain and future targets for increasing its titre. We have constructed a strain of S. cerevisiae that represents the first steps towards feasible industrial production of serotonin using a sustainable and environmentally friendly approach, paving the way for the development of similar biotechnological strategies in the future.